A 2019 report of anti-CD19/CD123 dual allogeneic CAR administered to three relapsed/refractory acute lymphoblastic leukemia adults achieved complete responses lasting 7–11 months (NCT03125577) (87). Here, CD19 is linked to acute lymphoblastic leukemia.